Toyama Chemical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Toyama Chemical Co., Ltd.
Keen On NASDAQ Slot, Concentra Looks To Scupper Jounce And Redx Merger
In February, Jounce’s future looked bleak after the failure of vopratelimab and fears that its finances would run out. Now, it has two suitors with Concentra making a bid to compete with an all-stock merger with the UK’s Redx.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
China Refuses Paxlovid Coverage Beyond March, Despite Strong Demand
China has rejected extending insurance coverage for Pfizer’s Paxlovid despite the US company's plans to continue supplying the oral COVID-19 antiviral, including through local manufacturing, amid strong demand and increasing severe infections in the country.
Finance Watch: VC Round Extensions Attractive While Stock Market Wobbles
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
- Other Names / Subsidiaries
- FUJIFILM Holdings Corporation
- FUJIFILM Group
- Cellular Dynamics International, Inc.
- Opsis Therapeutics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.